ARTICLE | Clinical News

InflaRx reports Phase IIa data of mAb against C5a for rare inflammatory skin disease

November 10, 2017 9:23 PM UTC

In September, InflaRx N.V. (NASDAQ:IFRX) reported data from a Phase IIa trial in 12 patients with moderate to severe hidradenitis suppurativa showing that IV IFX-1 (CaCP29) led to response rates of 75% at week 8 and 83% at week 20 as measured by Hidradenitis Suppurativa Clinical Response (HiSCR) scores. A response was defined as a reduction of ≥50% in inflammatory lesion count (abscesses and inflammatory nodules) and no increase in abscesses or draining fistulas compared to baseline. IFX-1 was well tolerated with no treatment-related adverse events reported. Patients received the mAb against complement 5a (C5a) once weekly for 8 weeks.

The open-label, Greek trial is evaluating safety as its primary endpoint. Secondary endpoints include response rate as measured by HiSCR scores, pharmacokinetics, Dermatology Life Quality Index (DLQI), Visual Analog Scale (VAS) disease score, VAS pain score and Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA)...

BCIQ Company Profiles

InflaRx N.V.

BCIQ Target Profiles

Complement 5a (C5a)